


Procedural Insights & First Learnings: the HTD perspective
























Vice-chair EFPIA HTA Working Group Director, HTA Policy, AstraZeneca

EAA Fall Convention, Nov 2025





Agenda

- The impact of JCA on HTDs
- Our observations to date
- Making JCA a success



For a HTD, JCA requires investment - more resources, more expenditure



PICO prediction

Systematic reviews

Analyses

Dossier

National

Expectations

1

2

3

4

5



Objective: identify all potential PICOs

Overpredict: limited consolidation insight Larger scope, more:

-Sub-populations

-Comparators
-Outcomes

-Outcomes

-Data extraction

Insufficient time from final PICOs

More (a lot more)

Multiple data readouts in oncology

More complex indirect comparisons

Safety

Substantially larger

Complex naming and filing system vs normal

National processes remain

Reduce redundancy

-More predictable PICOs

-Are all analyses used?

Remove clinical assessment

Faster decisions

Our observations to date

Eligibility

Timings

Explanation meeting

JSC

Secretariat questions

Complex pathways

Semi-clarified

Case studies required

Reducing in variability

Pragmatism

Reading of the PICOs

Limited scope for interaction

Limited opportunities


Requires large internal investment

Delayed responses



Closing remarks

Industry's commitment to ensuring JCA success



Thank you.



